当前位置: X-MOL 学术APMIS › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The panel of syntaxin 1 and insulinoma‐associated protein 1 outperforms classic neuroendocrine markers in pulmonary neuroendocrine neoplasms
APMIS ( IF 2.8 ) Pub Date : 2021-01-08 , DOI: 10.1111/apm.13113
Tamás Zombori 1 , Sándor Turkevi‐Nagy 1 , Anita Sejben 1 , Gréta Juhász‐Nagy 1 , Gábor Cserni 1, 2 , József Furák 3 , László Tiszlavicz 1 , László Krenács 4 , Bence Kővári 1, 5
Affiliation  

Syntaxin‐1 (STX1) is a recently described highly sensitive and specific neuroendocrine marker. We evaluated the applicability of STX1 as an immunohistochemical marker in pulmonary neuroendocrine neoplasms (NENs). We compared STX1 with established neuroendocrine markers, including insulinoma‐associated protein 1 (INSM1). Typical carcinoids (n = 33), atypical carcinoids (n = 7), small cell lung carcinomas ([SCLCs] n = 30), and large cell neuroendocrine lung carcinomas (n = 17) were immunostained using tissue microarray for STX1, chromogranin A, synaptophysin, CD56, and INSM1. Eighty‐four of eighty‐seven (96.5%) NENs showed STX1 positivity. Carcinoids and LCNECs typically presented a combined strong membranous and weak cytoplasmic staining pattern; cytoplasmic expression was predominately observed in SCLCs. The sensitivity of STX1 was 90% in SCLCs and 100% in typical carcinoids, atypical carcinoids, and large cell neuroendocrine lung carcinomas. The overall sensitivity of STX1 in pulmonary NENs was 96.6%, and the sensitivity of the other markers was as follows: chromogranin A (85.2%), synaptophysin (85.2%), CD56 (92.9%), and INSM1 (97.7%). STX1 was found to be an excellent neuroendocrine marker of pulmonary NENs, with sensitivity and specificity surpassing that of classic markers. We propose a panel of STX1 and INSM1 for the routine immunohistochemical workup of pulmonary NENs.

中文翻译:

在肺癌神经内分泌肿瘤中,syntaxin 1和胰岛素瘤相关蛋白1的研究结果优于经典的神经内分泌标志物

Syntaxin-1(STX1)是最近描述的高度敏感和特异的神经内分泌标记物。我们评估了STX1作为免疫组化标记物在肺神经内分泌肿瘤(NENs)中的适用性。我们将STX1与已建立的神经内分泌标记物(包括胰岛素瘤相关蛋白1(INSM1))进行了比较。使用组织芯片对STX1,嗜铬粒蛋白A进行免疫染色,对典型的类癌(n = 33),非典型类癌(n = 7),小细胞肺癌([SCLCs] n = 30)和大细胞神经内分泌性肺癌(n = 17)进行了染色。 ,突触素,CD56和INSM1。在八十七个(96.5%)NEN中,八十四个显示STX1阳性。类癌和LCNEC通常表现出强膜结合和弱胞浆染色模式。在SCLC中主要观察到细胞质表达。SLC1中STX1的敏感性为90%,典型类癌,非典型类癌和大细胞神经内分泌肺癌的敏感性为100%。STX1在肺NEN中的总体敏感性为96.6%,其他标记的敏感性如下:嗜铬粒蛋白A(85.2%),突触素(85.2%),CD56(92.9%)和INSM1(97.7%)。发现STX1是肺NEN的极好的神经内分泌标志物,其敏感性和特异性超过了经典标志物。我们建议对肺NENs进行常规免疫组化检查的STX1和INSM1小组。和INSM1(97.7%)。发现STX1是肺NEN的极好的神经内分泌标志物,其敏感性和特异性超过了经典标志物。我们建议对肺NENs进行常规免疫组化检查的STX1和INSM1小组。和INSM1(97.7%)。发现STX1是肺NEN的极好的神经内分泌标志物,其敏感性和特异性超过了经典标志物。我们建议对肺NENs进行常规免疫组化检查的STX1和INSM1小组。
更新日期:2021-03-10
down
wechat
bug